Given the limited investigations of the use of type 3 and 4 activators for the pharmacological management of LQTS, the next section will focus on a few examples of the most effective type 1 and 2 hERG agonists to date and review their reported antiarrhythmic benefits as well as associated pro‐arrhythmic risk for the management of LQTS. This evidence concerns the gene KCNH2 and familial long QT syndrome.